French Drug Sales Tax Now Set In Concrete For 1998

9 December 1997

France's National Assembly has now confirmed the imposition of a 2.5%"contribution" by the pharmaceutical industry, under Article 8, section 2 of th revized social security code (Marketletters passim). The contribution - or rather tax - will be levied on drugmakers' sales (excluding taxes) direct to pharmacists, with the specific exception of generic specialties.

The legislation goes on to state that when a drug company has not produced a sales declaration with the requisite detail in the time allotted, or has produced a "manifestly incorrect" declaration, the provisional rate of the contribution will be 10% - calculated on the last-known direct sales figure or by other means if this is necessary.

The 10% rate will also apply if a company is late in making declarations. Moreover, the levy will have to be paid by drugmakers on the last day of each quarter at the latest, on the basis of the sales achieved in the preceding quarter.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight